Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264283 | 0.80 | ALDH1A1 (0.50) | ALDH1A1RAB9AGAASMN1; SMN2POLB | |
| SCHEMBL1562741 | 0.77 | ALDH1A1 (0.59) | HSP90AA1ALDH1A1RAB9AGAAHTR3A | |
| SCHEMBL3262867 | 0.75 | ALKBH5 (0.54) | ALDH1A1RAB9AGAACYP1A2POLB | |
| SCHEMBL3835955 | 0.74 | ALDH1A1 (0.39) | ALDH1A1RAB9AGAASMN1; SMN2POLB | |
| SCHEMBL3262746 | 0.73 | NPC1 (0.42) | HSP90AA1ALDH1A1RAB9AGAAPOLB | |
| SCHEMBL28486186 | 0.73 | GAA (0.43) | HSP90AA1ALDH1A1RAB9AGAASMN1; SMN2 | |
| SCHEMBL11410044 | 0.70 | TSHR (0.64) | HSP90AA1ALDH1A1RAB9AGAAHTR3A | |
| SCHEMBL28345334 | 0.70 | MPI (0.64) | HSP90AA1ALDH1A1RAB9AGAAHTR3A | |
| SCHEMBL10373537 | 0.69 | MAPT (0.50) | ALDH1A1RAB9AGAASMN1; SMN2CYP1A2 | |
| SCHEMBL28477954 | 0.68 | KAT8 (0.65) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279175-B1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2015-05-13 | — | — | EP | disclosed |
| US-8492425-B2 | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-07-23 | — | — | US | disclosed |
| US-8329880-B2 | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-11 | — | — | US | disclosed |
| US-20110118253-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-19 | — | — | US | disclosed |
| US-20110071282-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-24 | — | — | US | disclosed |
| EP-2279175-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009130314-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112139-A1 | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071282-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRM1 | HSP90AA1 3342/4885ALDH1A1 2070/4885RAB9A 4522/4885 |
| US-20110118253-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRM1, OPRK1 | HSP90AA1 3020/4885ALDH1A1 654/4885RAB9A 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.